Donaco International Limited
Donaco International Limited Fundamental Analysis
Donaco International Limited (DNA.AX) shows strong financial fundamentals with a PE ratio of 1.50, profit margin of 93.76%, and ROE of 27.18%. The company generates $0.0B in annual revenue with strong year-over-year growth of 62.49%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 77.4/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze DNA.AX's fundamental strength across five key dimensions:
Efficiency Score
ExcellentDNA.AX demonstrates superior asset utilization.
Valuation Score
ExcellentDNA.AX trades at attractive valuation levels.
Growth Score
ModerateDNA.AX shows steady but slowing expansion.
Financial Health Score
ModerateDNA.AX shows balanced financial health with some risks.
Profitability Score
ExcellentDNA.AX achieves industry-leading margins.
Key Financial Metrics
Is DNA.AX Expensive or Cheap?
P/E Ratio
DNA.AX trades at 1.50 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, DNA.AX's PEG of 0.28 indicates potential undervaluation.
Price to Book
The market values Donaco International Limited at 0.37 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 1.35 times EBITDA. This is generally considered low.
How Well Does DNA.AX Make Money?
Net Profit Margin
For every $100 in sales, Donaco International Limited keeps $93.76 as profit after all expenses.
Operating Margin
Core operations generate 39.29 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $27.18 in profit for every $100 of shareholder equity.
ROA
Donaco International Limited generates $18.45 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Donaco International Limited generates strong operating cash flow of $15.03M, reflecting robust business health.
Free Cash Flow
Donaco International Limited generates strong free cash flow of $14.70M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.01 in free cash annually.
FCF Yield
DNA.AX converts 26.47% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
1.50
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.28
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.37
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.40
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.15
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.77
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.27
vs 25 benchmark
ROA
Return on assets percentage
0.18
vs 25 benchmark
ROCE
Return on capital employed
0.10
vs 25 benchmark
How DNA.AX Stacks Against Its Sector Peers
| Metric | DNA.AX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 1.50 | 24.38 | Better (Cheaper) |
| ROE | 27.18% | 1159.00% | Weak |
| Net Margin | 93.76% | -390.00% (disorted) | Strong |
| Debt/Equity | 0.15 | 0.78 | Strong (Low Leverage) |
| Current Ratio | 0.77 | 2.60 | Weak Liquidity |
| ROA | 18.45% | -30346.00% (disorted) | Strong |
DNA.AX outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Donaco International Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-69.39%
Industry Style: Cyclical, Growth, Discretionary
DecliningEPS CAGR
112.75%
Industry Style: Cyclical, Growth, Discretionary
High GrowthFCF CAGR
-60.89%
Industry Style: Cyclical, Growth, Discretionary
Declining